JOHNSON & JOHNSON - FORM 8-K - EX-99.2O - EXHIBIT

Attached files

file	filename
8-K - 8-K - JOHNSON & JOHNSON	a4q20128kcover.htm
EX-99.15 - EXHIBIT - JOHNSON & JOHNSON	a4q20128kexhibit9915.htm

Exhibit 99.2O



Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	FOURTH QUARTER

	2012				2011						Percent
				Percent					Percent		Increase
	Amount			to Sales	Amount				to Sales		(Decrease)
Sales to customers	$	17,558		100.0	$	16,255			100.0		8.0
Cost of products sold	6,003			34.2	5,338				32.8		12.5
Selling, marketing and administrative expenses	5,661			32.2	5,458				33.6		3.7
Research and development expense	2,331			13.3	2,155				13.3		8.2
In-process research and development	55			0.3	—				—
Interest (income) expense, net	89			0.5	148				0.9
Other (income) expense, net	319			1.8	2,858				17.6
Restructuring (income) expense, net	—			—	(20		)		(0.1	)
Earnings before provision for taxes on income	3,100			17.7	318				1.9		874.8
Provision for taxes on income	533			3.1	100				0.6		433.0
Net earnings	2,567			14.6	218				1.3		1,077.5
Add: Net loss attributable to noncontrolling interest	—			—	—				—
Net earnings attributable to Johnson & Johnson	$	2,567		14.6	$	218			1.3		1,077.5

Net earnings per share attributable to Johnson & Johnson (Diluted)	$	0.91			$	0.08					1,037.5

Average shares outstanding (Diluted)	2,833.4				2,768.9

Effective tax rate	17.2		%		31.4			%

Adjusted earnings before provision for taxes and net earnings attributable to Johnson & Johnson ^{(1) (A)}
Earnings before provision for taxes on income	$	4,115		23.4	$	3,657			22.5		12.5
Net earnings attributable to Johnson & Johnson	$	3,376		19.2	$	3,129			19.2		7.9
Net earnings per share attributable to Johnson & Johnson (Diluted)	$	1.19			$	1.13					5.3
Effective tax rate	18.0		%		14.4			%

⁽¹⁾ See Reconciliation of Non-GAAP Financial Measures.

^(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings attributable to Johnson & Johnson," "adjusted net earnings per share attributable to Johnson & Johnson (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings attributable to Johnson & Johnson, net earnings per share attributable to Johnson & Johnson (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings attributable to Johnson & Johnson, net earnings per share attributable to Johnson & Johnson (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings attributable to Johnson & Johnson, adjusted net earnings per share attributable to Johnson & Johnson (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. These non-GAAP financial measures are presented solely to permit investors to more fully understand how management assesses the performance of the Company. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.



Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	TWELVE MONTHS

	2012				2011				Percent
				Percent				Percent	Increase
	Amount			to Sales	Amount			to Sales	(Decrease)
Sales to customers	$	67,224		100.0	$	65,030		100.0	3.4
Cost of products sold	21,658			32.2	20,360			31.3	6.4
Selling, marketing and administrative expenses	20,869			31.0	20,969			32.3	(0.5	)
Research and development expense	7,665			11.4	7,548			11.6	1.6
In-process research and development	1,163			1.7	—			—
Interest (income) expense, net	468			0.7	480			0.7
Other (income) expense, net	1,626			2.5	2,743			4.2
Restructuring (income) expense, net	—			—	569			0.9
Earnings before provision for taxes on income	13,775			20.5	12,361			19.0	11.4
Provision for taxes on income	3,261			4.9	2,689			4.1	21.3
Net earnings	10,514			15.6	9,672			14.9	8.7
Add: Net loss attributable to noncontrolling interest	339			0.5	—			—
Net earnings attributable to Johnson & Johnson	$	10,853		16.1	$	9,672		14.9	12.2

Net earnings per share attributable to Johnson & Johnson (Diluted)	$	3.86			$	3.49			10.6

Average shares outstanding (Diluted)	2,812.6				2,775.3

Effective tax rate	23.7		%		21.8		%

Adjusted earnings before provision for taxes and net earnings attributable to Johnson & Johnson ^{(1) (A)}
Earnings before provision for taxes on income	$	18,214		27.1	$	17,353		26.7	5.0
Net earnings attributable to Johnson & Johnson	$	14,345		21.3	$	13,867		21.3	3.4
Net earnings per share attributable to Johnson & Johnson (Diluted)	$	5.10			$	5.00			2.0
Effective tax rate	21.2		%		20.1		%

⁽¹⁾ See Reconciliation of Non-GAAP Financial Measures.

^(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings attributable to Johnson & Johnson," "adjusted net earnings per share attributable to Johnson & Johnson (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings attributable to Johnson & Johnson, net earnings per share attributable to Johnson & Johnson (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings attributable to Johnson & Johnson, net earnings per share attributable to Johnson & Johnson (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings attributable to Johnson & Johnson, adjusted net earnings per share attributable to Johnson & Johnson (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. These non-GAAP financial measures are presented solely to permit investors to more fully understand how management assesses the performance of the Company. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	FOURTH QUARTER
				Percent Change
	2012		2011	Total			Operations		Currency
Sales to customers by
segment of business

Consumer
U.S.	$	1,203	1,248	(3.6	)	%	(3.6	)	—
International	2,449		2,420	1.2			3.2		(2.0	)
	3,652		3,668	(0.4	)		0.9		(1.3	)

Pharmaceutical
U.S.	3,013		2,887	4.4			4.4		—
International	3,512		3,207	9.5			12.1		(2.6	)
	6,525		6,094	7.1			8.5		(1.4	)

Med Devices & Diagnostics
U.S.	3,244		2,850	13.8			13.8		—
International	4,137		3,643	13.6			15.8		(2.2	)
	7,381		6,493	13.7			14.9		(1.2	)

U.S.	7,460		6,985	6.8			6.8		—
International	10,098		9,270	8.9			11.2		(2.3	)
Worldwide	$	17,558	16,255	8.0		%	9.3		(1.3	)



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	TWELVE MONTHS
				Percent Change
	2012		2011	Total			Operations		Currency
Sales to customers by
segment of business

Consumer
U.S.	$	5,046	5,151	(2.0	)	%	(2.0	)	—
International	9,401		9,732	(3.4	)		1.9		(5.3	)
	14,447		14,883	(2.9	)		0.5		(3.4	)

Pharmaceutical
U.S.	12,421		12,386	0.3			0.3		—
International	12,930		11,982	7.9			13.6		(5.7	)
	25,351		24,368	4.0			6.8		(2.8	)

Med Devices & Diagnostics
U.S.	12,363		11,371	8.7			8.7		—
International	15,063		14,408	4.5			8.6		(4.1	)
	27,426		25,779	6.4			8.7		(2.3	)

U.S.	29,830		28,908	3.2			3.2		—
International	37,394		36,122	3.5			8.4		(4.9	)
Worldwide	$	67,224	65,030	3.4		%	6.1		(2.7	)



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	FOURTH QUARTER
				Percent Change
	2012		2011	Total		Operations	Currency
Sales to customers by
geographic area

U.S.	$	7,460	6,985	6.8	%	6.8	—

Europe	4,603		4,279	7.6		10.4	(2.8	)
Western Hemisphere excluding U.S.	1,941		1,688	15.0		18.7	(3.7	)
Asia-Pacific, Africa	3,554		3,303	7.6		8.5	(0.9	)
International	10,098		9,270	8.9		11.2	(2.3	)

Worldwide	$	17,558	16,255	8.0	%	9.3	(1.3	)



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	TWELVE MONTHS
				Percent Change
	2012		2011	Total			Operations	Currency
Sales to customers by
geographic area

U.S.	$	29,830	28,908	3.2		%	3.2	—

Europe	16,945		17,129	(1.1	)		5.8	(6.9	)
Western Hemisphere excluding U.S.	7,207		6,418	12.3			19.0	(6.7	)
Asia-Pacific, Africa	13,242		12,575	5.3			6.7	(1.4	)
International	37,394		36,122	3.5			8.4	(4.9	)

Worldwide	$	67,224	65,030	3.4		%	6.1	(2.7	)



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
	Fourth Quarter				% Incr. /
(Dollars in Millions Except Per Share Data)	2012		2011		(Decr.)

Earnings before provision for taxes on income - as reported	$	3,100	318		874.8	%

Net litigation loss (gain)	471		2,656

In-process research and development	55		14

Synthes integration/transaction costs and currency related	406		277

Intangible asset write-downs and other adjustments	—		—

DePuy ASR™ Hip program	83		412

Restructuring	—		(20	)

Earnings before provision for taxes on income - as adjusted	$	4,115	3,657		12.5	%

Net Earnings attributable to Johnson & Johnson - as reported	$	2,567	218		1,077.5	%

Net litigation loss (gain)	371		2,239

In-process research and development	59		11

Synthes integration/transaction costs and currency related	306		338

Intangible asset write-downs and other adjustments	—		—

DePuy ASR™ Hip program	73		336

Restructuring	—		(13	)

Net Earnings attributable to Johnson & Johnson - as adjusted	$	3,376	3,129		7.9	%

Diluted Net Earnings per share attributable to Johnson & Johnson - as reported	$	0.91	0.08		1,037.5	%

Net litigation loss (gain)	0.13		0.81

In-process research and development	0.02		—

Synthes integration/transaction costs and currency related	0.11		0.12

Intangible asset write-downs and other adjustments	—		—

DePuy ASR™ Hip program	0.02		0.12

Restructuring	—		—

Diluted Net Earnings per share attributable to Johnson & Johnson - as adjusted	$	1.19	1.13		5.3	%

The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
	Twelve Months				% Incr. /
(Dollars in Millions Except Per Share Data)	2012			2011	(Decr.)

Earnings before provision for taxes on income - as reported	$	13,775		12,361	11.4	%

Net litigation loss (gain)	1,229			3,310

In-process research and development	1,163			14

Synthes integration/transaction costs and currency related	1,028			491

Intangible asset write-downs and other adjustments	909			—

DePuy ASR™ Hip program	110			521

Restructuring	—			656

Earnings before provision for taxes on income - as adjusted	$	18,214		17,353	5.0	%

Net Earnings attributable to Johnson & Johnson - as reported	$	10,853		9,672	12.2	%

Net litigation loss (gain)	1,052			2,745

In-process research and development	743		⁽¹⁾	11

Synthes integration/transaction costs and currency related	899			477

Intangible asset write-downs and other adjustments	701			—

DePuy ASR™ Hip program	97			426

Restructuring	—			536

Net Earnings attributable to Johnson & Johnson - as adjusted	$	14,345		13,867	3.4	%

Diluted Net Earnings per share attributable to Johnson & Johnson - as reported	$	3.86		3.49	10.6	%

Net litigation loss (gain)	0.37			0.99

In-process research and development	0.27			—

Synthes integration/transaction costs and currency related	0.32			0.17

Intangible asset write-downs and other adjustments	0.25			—

DePuy ASR™ Hip program	0.03			0.16

Restructuring	—			0.19

Diluted Net Earnings per share attributable to Johnson & Johnson - as adjusted	$	5.10		5.00	2.0	%

⁽¹⁾ Amount includes third quarter in-process research and development charge of $679M related to bapineuzumab IV offset by $339M reported as net loss attributable to noncontrolling interest

The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		FOURTH QUARTER
				% Change
		2012	2011	Reported		Operational⁽¹⁾		Currency
CONSUMER SEGMENT⁽²⁾

BABY CARE
US	$	103	103	0.0	%	0.0	%	—	%
Intl		469	465	0.9		3.5		(2.6	)
WW		572	568	0.7		2.8		(2.1	)

ORAL CARE
US		165	173	(4.6)		(4.6)		—
Intl		251	239	5.0		6.6		(1.6	)
WW		416	412	1.0		2.0		(1.0	)

OTC/NUTRITIONALS
US		356	370	(3.8	)	(3.8	)	—
Intl		802	766	4.7		5.7		(1.0	)
WW		1,158	1,136	1.9		2.6		(0.7	)

SKIN CARE
US		385	403	(4.5	)	(4.5	)	—
Intl		509	541	(5.9	)	(3.4	)	(2.5	)
WW		894	944	(5.3	)	(3.9	)	(1.4	)

WOMEN'S HEALTH
US		82	89	(7.9	)	(7.9	)	—
Intl		325	309	5.2		9.4		(4.2	)
WW		407	398	2.3		5.5		(3.2	)

WOUND CARE/OTHER
US		112	110	1.8		1.8		—
Intl		93	100	(7.0	)	(8.0	)	1.0
WW		205	210	(2.4	)	(2.9	)	0.5

TOTAL CONSUMER
US		1,203	1,248	(3.6	)	(3.6	)	—
Intl		2,449	2,420	1.2		3.2		(2.0	)
WW	$	3,652	3,668	(0.4	)%	0.9	%	(1.3	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		FOURTH QUARTER
					% Change
		2012	2011		Reported		Operational⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4)}

IMMUNOLOGY
US	$	1,448	1,401		3.4	%	3.4	%	—	%
Intl		528	395		33.7		35.7		(2.0	)
WW		1,976	1,796		10.0		10.4		(0.4	)
REMICADE
US		871	776		12.2		12.2		—
US Exports⁽³⁾		347	437		(20.6	)	(20.6	)	—
Intl		286	215		33.0		34.4		(1.4	)
WW		1,504	1,428		5.3		5.5		(0.2	)
SIMPONI
US		72	62		16.1		16.1		—
Intl		109	57		91.2		96.8		(5.6	)
WW		181	119		52.1		54.8		(2.7	)
STELARA
US		158	126		25.4		25.4		—
Intl		111	81		37.0		40.1		(3.1	)
WW		269	207		30.0		31.2		(1.2	)
OTHER IMMUNOLOGY
US		—	—		—		—		—
Intl		22	42		(47.6	)	(49.4	)	1.8
WW		22	42		(47.6	)	(49.4	)	1.8

INFECTIOUS DISEASES
US		236	210		12.4		12.4		—
Intl		620	506		22.5		26.7		(4.2	)
WW		856	716		19.6		22.6		(3.0	)
INTELENCE
US		46	45		2.2		2.2		—
Intl		38	38		0.0		1.7		(1.7	)
WW		84	83		1.2		2.0		(0.8	)
LEVAQUIN/FLOXIN
US		—	(6	)	*		*		—
Intl		10	11		(9.1	)	(10.5	)	1.4
WW		10	5		100.0		97.2		2.8
PREZISTA
US		165	143		15.4		15.4		—
Intl		188	173		8.7		12.2		(3.5	)
WW		353	316		11.7		13.6		(1.9	)
OTHER INFECTIOUS DISEASES
US		25	28		(10.7	)	(10.7	)	—
Intl		384	284		35.2		40.5		(5.3	)
WW		409	312		31.1		35.9		(4.8	)

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		FOURTH QUARTER
				% Change
		2012	2011	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4) (Continued)}

NEUROSCIENCE
US	$	601	611	(1.6	)%	(1.6	)%	—	%
Intl		1,088	1,128	(3.5	)	(1.6	)	(1.9	)
WW		1,689	1,739	(2.9	)	(1.6	)	(1.3	)
CONCERTA/METHYLPHENIDATE
US		116	155	(25.2	)	(25.2	)	—
Intl		127	119	6.7		8.1		(1.4	)
WW		243	274	(11.3	)	(10.7	)	(0.6	)
INVEGA
US		76	66	15.2		15.2		—
Intl		71	59	20.3		23.0		(2.7	)
WW		147	125	17.6		18.9		(1.3	)
INVEGA SUSTENNA/XEPLION
US		132	99	33.3		33.3		—
Intl		96	36	*		*		(2.4	)
WW		228	135	68.9		69.9		(1.0	)
RISPERDAL CONSTA
US		103	108	(4.6	)	(4.6	)	—
Intl		255	277	(7.9	)	(5.8	)	(2.1	)
WW		358	385	(7.0	)	(5.5	)	(1.5	)
OTHER NEUROSCIENCE
US		174	183	(4.9	)	(4.9	)	—
Intl		539	637	(15.4	)	(13.7	)	(1.7	)
WW		713	820	(13.0	)	(11.7	)	(1.3	)

ONCOLOGY
US		135	95	42.1		42.1		—
Intl		684	468	46.2		49.7		(3.5	)
WW		819	563	45.5		48.5		(3.0	)
DOXIL/CAELYX
US		21	10	*		*		—
Intl		9	29	(69.0	)	(68.3	)	(0.7	)
WW		30	39	(23.1	)	(22.6	)	(0.5	)
VELCADE
US		—	—	—		—		—
Intl		502	352	42.6		47.6		(5.0	)
WW		502	352	42.6		47.6		(5.0	)
ZYTIGA
US		114	85	34.1		34.1		—
Intl		150	67	*		*		(3.8	)
WW		264	152	73.7		75.8		(2.1	)
OTHER ONCOLOGY
US		—	—	—		—		—
Intl		23	20	15.0		18.8		(3.8	)
WW		23	20	15.0		18.8		(3.8	)
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		FOURTH QUARTER
				% Change
		2012	2011	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4) (Continued)}

TOTAL OTHER
US	$	593	570	4.0	%	4.0	%	—	%
Intl		592	710	(16.6	)	(15.5	)	(1.1	)
WW		1,185	1,280	(7.4	)	(6.8	)	(0.6	)
ACIPHEX/PARIET
US		92	110	(16.4	)	(16.4	)	—
Intl		94	144	(34.7	)	(33.9	)	(0.8	)
WW		186	254	(26.8	)	(26.4	)	(0.4	)
PROCRIT/EPREX
US		171	191	(10.5	)	(10.5	)	—
Intl		155	177	(12.4	)	(11.0	)	(1.4	)
WW		326	368	(11.4	)	(10.7	)	(0.7	)
OTHER
US		330	269	22.7		22.7		—
Intl		343	389	(11.8	)	(10.8	)	(1.0	)
WW		673	658	2.3		2.9		(0.6	)

TOTAL PHARMACEUTICAL
US		3,013	2,887	4.4		4.4		—
Intl		3,512	3,207	9.5		12.1		(2.6	)
WW	$	6,525	6,094	7.1	%	8.5	%	(1.4	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		FOURTH QUARTER
				% Change
		2012	2011	Reported		Operational ⁽¹⁾		Currency
MEDICAL DEVICES AND DIAGNOSTICS ^{(2) (4)}

CARDIOVASCULAR CARE
US	$	186	191	(2.6	)%	(2.6	)%	—	%
Intl		320	349	(8.3	)	(6.6	)	(1.7	)
WW		506	540	(6.3	)	(5.2	)	(1.1	)

DIABETES CARE
US		295	330	(10.6	)	(10.6	)	—
Intl		349	340	2.6		5.2		(2.6	)
WW		644	670	(3.9	)	(2.6	)	(1.3	)

DIAGNOSTICS
US		258	280	(7.9	)	(7.9	)	—
Intl		272	274	(0.7	)	1.3		(2.0	)
WW		530	554	(4.3	)	(3.3	)	(1.0	)

INFECTION PREVENTION/OTHER
US		86	94	(8.5	)	(8.5	)	—
Intl		160	144	11.1		13.6		(2.5	)
WW		246	238	3.4		4.9		(1.5	)

ORTHOPAEDICS
US		1,246	775	60.8		60.8		—
Intl		1,142	678	68.4		70.1		(1.7	)
WW		2,388	1,453	64.3		65.1		(0.8	)

SPECIALTY SURGERY
US		326	327	(0.3	)	(0.3	)	—
Intl		329	307	7.2		9.5		(2.3	)
WW		655	634	3.3		4.4		(1.1	)

SURGICAL CARE
US		618	639	(3.3	)	(3.3	)	—
Intl		1,049	1,055	(0.6	)	1.9		(2.5	)
WW		1,667	1,694	(1.6	)	0.0		(1.6	)

VISION CARE
US		229	214	7.0		7.0		—
Intl		516	496	4.0		6.1		(2.1	)
WW		745	710	4.9		6.4		(1.5	)

TOTAL MEDICAL DEVICES AND DIAGNOSTICS
US		3,244	2,850	13.8		13.8		—
Intl		4,137	3,643	13.6		15.8		(2.2	)
WW	$	7,381	6,493	13.7	%	14.9	%	(1.2	)%
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		TWELVE MONTHS
				% Change
		2012	2011	Reported		Operational⁽¹⁾		Currency
CONSUMER SEGMENT⁽²⁾

BABY CARE
US	$	412	418	(1.4	)%	(1.4	)%	—	%
Intl		1,842	1,922	(4.2	)	1.1		(5.3	)
WW		2,254	2,340	(3.7	)	0.6		(4.3	)

ORAL CARE
US		641	656	(2.3	)	(2.3	)	—
Intl		983	968	1.5		6.9		(5.4	)
WW		1,624	1,624	0.0		3.2		(3.2	)

OTC/NUTRITIONALS
US		1,424	1,429	(0.3	)	(0.3	)	—
Intl		2,930	2,973	(1.4	)	3.4		(4.8	)
WW		4,354	4,402	(1.1	)	2.1		(3.2	)

SKIN CARE
US		1,699	1,654	2.7		2.7		—
Intl		1,919	2,061	(6.9	)	(2.0	)	(4.9	)
WW		3,618	3,715	(2.6	)	0.1		(2.7	)

WOMEN'S HEALTH
US		336	439	(23.5	)	(23.5	)	—
Intl		1,289	1,353	(4.7	)	2.3		(7.0	)
WW		1,625	1,792	(9.3	)	(4.0	)	(5.3	)

WOUND CARE/OTHER
US		534	555	(3.8	)	(3.8	)	—
Intl		438	455	(3.7	)	0.6		(4.3	)
WW		972	1,010	(3.8	)	(1.8	)	(2.0	)

TOTAL CONSUMER
US		5,046	5,151	(2.0	)	(2.0	)	—
Intl		9,401	9,732	(3.4	)	1.9		(5.3	)
WW	$	14,447	14,883	(2.9	)%	0.5	%	(3.4	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		TWELVE MONTHS
				% Change
		2012	2011	Reported		Operational⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4)}

IMMUNOLOGY
US	$	5,972	5,751	3.8	%	3.8	%	—	%
Intl		1,902	1,047	81.7		86.3		(4.6	)
WW		7,874	6,798	15.8		16.9		(1.1	)
REMICADE
US		3,583	3,276	9.4		9.4		—
US Exports⁽³⁾		1,470	1,797	(18.2	)	(18.2	)	—
Intl		1,086	419	*		*		(4.5	)
WW		6,139	5,492	11.8		12.6		(0.8	)
SIMPONI
US		292	235	24.3		24.3		—
Intl		315	175	80.0		87.5		(7.5	)
WW		607	410	48.0		51.2		(3.2	)
STELARA
US		627	443	41.5		41.5		—
Intl		398	295	34.9		42.4		(7.5	)
WW		1,025	738	38.9		41.9		(3.0	)
OTHER IMMUNOLOGY
US		—	—	—		—		—
Intl		103	158	(34.8	)	(33.0	)	(1.8	)
WW		103	158	(34.8	)	(33.0	)	(1.8	)

INFECTIOUS DISEASES
US		974	1,401	(30.5	)	(30.5	)	—
Intl		2,220	1,788	24.2		32.1		(7.9	)
WW		3,194	3,189	0.2		4.6		(4.4	)
INTELENCE
US		176	163	8.0		8.0		—
Intl		173	151	14.6		22.2		(7.6	)
WW		349	314	11.1		14.8		(3.7	)
LEVAQUIN/FLOXIN
US		35	579	(94.0	)	(94.0	)	—
Intl		40	44	(9.1	)	(5.8	)	(3.3	)
WW		75	623	(88.0	)	(87.8	)	(0.2	)
PREZISTA
US		672	529	27.0		27.0		—
Intl		742	682	8.8		16.3		(7.5	)
WW		1,414	1,211	16.8		21.0		(4.2	)
OTHER INFECTIOUS DISEASES
US		91	130	(30.0	)	(30.0	)	—
Intl		1,265	911	38.9		47.3		(8.4	)
WW		1,356	1,041	30.3		37.7		(7.4	)

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		TWELVE MONTHS
				% Change
		2012	2011	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4) (Continued)}

NEUROSCIENCE
US	$	2,611	2,617	(0.2	)%	(0.2	)%	—	%
Intl		4,107	4,331	(5.2	)	(0.8	)	(4.4	)
WW		6,718	6,948	(3.3	)	(0.5	)	(2.8	)
CONCERTA/METHYLPHENIDATE
US		609	822	(25.9	)	(25.9	)	—
Intl		464	446	4.0		8.8		(4.8	)
WW		1,073	1,268	(15.4	)	(13.7	)	(1.7	)
INVEGA
US		299	285	4.9		4.9		—
Intl		251	214	17.3		22.0		(4.7	)
WW		550	499	10.2		12.2		(2.0	)
INVEGA SUSTENNA/XEPLION
US		482	319	51.1		51.1		—
Intl		314	59	*		*		(5.7	)
WW		796	378	*		*		(2.2	)
RISPERDAL CONSTA
US		439	443	(0.9	)	(0.9	)	—
Intl		986	1,140	(13.5	)	(8.6	)	(4.9	)
WW		1,425	1,583	(10.0	)	(6.4	)	(3.6	)
OTHER NEUROSCIENCE
US		782	748	4.5		4.5		—
Intl		2,092	2,472	(15.4	)	(11.9	)	(3.5	)
WW		2,874	3,220	(10.7	)	(8.0	)	(2.7	)

ONCOLOGY
US		506	331	52.9		52.9		—
Intl		2,123	1,717	23.6		29.7		(6.1	)
WW		2,629	2,048	28.4		33.3		(4.9	)
DOXIL/CAELYX
US		43	140	(69.3	)	(69.3	)	—
Intl		40	262	(84.7	)	(83.5	)	(1.2	)
WW		83	402	(79.4	)	(78.6	)	(0.8	)
VELCADE
US		—	—	—		—		—
Intl		1,500	1,274	17.7		24.5		(6.8	)
WW		1,500	1,274	17.7		24.5		(6.8	)
ZYTIGA
US		463	191	*		*		—
Intl		498	110	*		*		(7.0	)
WW		961	301	*		*		(3.7	)
OTHER ONCOLOGY
US		—	—	—		—		—
Intl		85	71	19.7		25.5		(5.8	)
WW		85	71	19.7		25.5		(5.8	)
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		TWELVE MONTHS
				% Change
		2012	2011	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4) (Continued)}

TOTAL OTHER
US	$	2,358	2,286	3.1	%	3.1	%	—	%
Intl		2,578	3,099	(16.8	)	(12.4	)	(4.4	)
WW		4,936	5,385	(8.3	)	(5.8	)	(2.5	)
ACIPHEX/PARIET
US		372	414	(10.1	)	(10.1	)	—
Intl		463	561	(17.5	)	(11.8	)	(5.7	)
WW		835	975	(14.4	)	(11.1	)	(3.3	)
PROCRIT/EPREX
US		805	814	(1.1	)	(1.1	)	—
Intl		657	809	(18.8	)	(13.7	)	(5.1	)
WW		1,462	1,623	(9.9	)	(7.4	)	(2.5	)
OTHER
US		1,181	1,058	11.6		11.6		—
Intl		1,458	1,729	(15.7	)	(12.1	)	(3.6	)
WW		2,639	2,787	(5.3	)	(3.1	)	(2.2	)

TOTAL PHARMACEUTICAL
US		12,421	12,386	0.3		0.3		—
Intl		12,930	11,982	7.9		13.6		(5.7	)
WW	$	25,351	24,368	4.0	%	6.8	%	(2.8	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		TWELVE MONTHS
				% Change
		2012	2011	Reported		Operational ⁽¹⁾		Currency
MEDICAL DEVICES AND DIAGNOSTICS ^{(2) (4)}

CARDIOVASCULAR CARE
US	$	752	841	(10.6	)%	(10.6	)%	—	%
Intl		1,233	1,447	(14.8	)	(11.5	)	(3.3	)
WW		1,985	2,288	(13.2	)	(11.1	)	(2.1	)
DIABETES CARE
US		1,312	1,312	0.0		0.0		—
Intl		1,304	1,340	(2.7	)	2.8		(5.5	)
WW		2,616	2,652	(1.4	)	1.4		(2.8	)
DIAGNOSTICS
US		1,025	1,091	(6.0	)	(6.0	)	—
Intl		1,044	1,073	(2.7	)	1.0		(3.7	)
WW		2,069	2,164	(4.4	)	(2.6	)	(1.8	)
INFECTION PREVENTION/OTHER
US		399	377	5.8		5.8		—
Intl		553	529	4.5		8.2		(3.7	)
WW		952	906	5.1		7.2		(2.1	)
ORTHOPAEDICS
US		4,144	3,093	34.0		34.0		—
Intl		3,655	2,716	34.6		38.7		(4.1	)
WW		7,799	5,809	34.3		36.2		(1.9	)
SPECIALTY SURGERY
US		1,297	1,226	5.8		5.8		—
Intl		1,229	1,181	4.1		8.9		(4.8	)
WW		2,526	2,407	4.9		7.2		(2.3	)
SURGICAL CARE
US		2,415	2,465	(2.0	)	(2.0	)	—
Intl		4,068	4,172	(2.5	)	2.1		(4.6	)
WW		6,483	6,637	(2.3	)	0.6		(2.9	)
VISION CARE
US		1,019	966	5.5		5.5		—
Intl		1,977	1,950	1.4		3.7		(2.3	)
WW		2,996	2,916	2.7		4.3		(1.6	)

TOTAL MEDICAL DEVICES AND DIAGNOSTICS
US		12,363	11,371	8.7		8.7		—
Intl		15,063	14,408	4.5		8.6		(4.1	)
WW	$	27,426	25,779	6.4	%	8.7	%	(2.3	)%
*Percentage greater than 100%
⁽¹⁾Operational growth excludes the effect of currency
⁽²⁾ Select areas (unaudited)
⁽³⁾Reported as U.S. sales
⁽⁴⁾Prior year amounts have been reclassified to conform to current year product disclosure

Attached files

Stock widget

Investing forum

JOHNSON & JOHNSON Reports

JOHNSON & JOHNSON - FORM 8-K - EX-99.2O - EXHIBIT - January 22, 2013

Attached files

Stock widget

Investing forum

JOHNSON & JOHNSON Reports